REG - Roquefort Theraptcs. - Director/PDMR Shareholding

Roquefort TherapeuticsAnnouncement

24/11/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251124:nRSX6299Ia&default-theme=true

RNS Number : 6299I  Roquefort Therapeutics PLC  24 November 2025

24 November 2025

 

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

 

Director/PDMR Shareholding

 

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company,
advises that Dr Darrin Disley, Interim Managing Director, has purchased
ordinary shares of £0.01 each in the Company ("Ordinary Shares"), as detailed
below:

 

 Number of Ordinary Shares Acquired  Average Price Paid per Share  Total Consideration Paid  Number of Ordinary Shares Now Held  % of Company's Issued Capital
 5,000,000                           1.70 pence                    £85,000.00                7,024,196                           4.46%

 

-ENDS-

Enquiries:
 Roquefort Therapeutics plc                               +44 (0)20 3918 8633
 Stephen West (Chairman) / Dr Darrin Disley (Interim MD)
 SP Angel Corporate Finance LLP (Joint Broker)            +44 (0) 20 3470 0470

 David Hignell / Vadim Alexandre / Devik Mehta
 Shard Capital Partners LLP (Joint Broker)                +44 (0)20 4530 6926

 Damon Heath
 Burson Buchanan (Public Relations)                       +44 (0)20 7466 5000

 Ben Romney / Jamie Hooper
 Peak IR (Investor Relations)                             +33 (0)7 44 44 15 42

 Seb Wykeham

 

LEI: ‎254900P4SISIWOR9RH34

 

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is focused on completing the proposed
transaction with A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc. which
will result in the Company acquiring the exclusive licence rights to AO-252, a
novel first-in-class, first-in-human new drug alternative targeting the TACC3
protein for the treatment of certain cancers, most recently announced by the
Company on 18 November 2025.

 

For further information on Roquefort Therapeutics,
please visit www.roquefortplc.com (http://www.roquefortplc.com/)

 

This announcement contains inside information for the purposes of Article 7 of
the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it
forms part of UK domestic law by virtue of the European Union (Withdrawal) Act
2018, as amended ("UK MAR").

The notification below, made in accordance with the requirements of the UK
MAR, provides further detail:

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 1   Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Darrin Disley
 2   Reason for the notification
 a)  Position/status                                              Interim Managing Director
 b)  Initial notification /Amendment                              Initial
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Roquefort Therapeutics plc
 b)  LEI                                                          254900P4SISIWOR9RH34
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of £0.01 par value

     Identification code

                                                                  ISIN: GB00BMDQ2T15
 b)  Nature of the transaction                                    Purchase of 5,000,000 ordinary shares
 c)  Price(s) and volume(s)                                       Price(s)                     Volume(s)
                                                                  1.70 pence per share         5,000,000
 d   Aggregated information

     - Aggregated volume                                          -       5,000,000

     - Price                                                      -       1. 70p
 e)  Date of the transactions                                     21 November 2025
 f)  Place of the transactions                                    London Stock Exchange (XLON); Main Market

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBRBDBDSDDGUX



            Copyright 2019 Regulatory News Service, all rights reserved